1-3 of 3
Oliver G. Ottmann, PhD
Close
Sort by
Journal Articles

Establishment and Characterization of a tel/abl Rearrangement Responsible for Imatinib Sensitivity in bcr/abl Negative Acute Lymphoblastic Leukemia.

Jörg Bäumler, PhD, J.H. Frederik Falkenburg, PhD, Marianke L.J. van Schie, Karoly Szuhai, PhD, Martine Pape, Sina Droll, Oliver G. Ottmann, PhD, Bart Nijmeijer, PhD
Journal: Blood
Blood (2007) 110 (11): 4280.
https://doi.org/10.1182/blood.V110.11.4280.4280
Published: 2007
Journal Articles

Bim Is the Critical, and Bad and Bmf Are the Ancillary BH3-Only Proteins for Imatinib Mesylate-Induced Apoptosis of Bcr/Abl-Positive Leukemias.

Junya Kuroda, PhD, MD, Hamsa Puthalakath, PhD, Philippe Bouillet, PhD, Mark S. Cragg, PhD, Priscilla N. Kelly, Andrew W. Roberts, PhD, MD, Shinya Kimura, PhD, MD, Oliver G. Ottmann, PhD, MD, Andreas Strasser, PhD
Journal: Blood
Blood (2005) 106 (11): 2876.
https://doi.org/10.1182/blood.V106.11.2876.2876
Published: 2005
Journal Articles

Priming with Granulocyte Colony-Stimulating Factor (G-CSF) Has No Impact on Treatment Outcome but Impairs Mobilization of Peripheral Blood Stem Cells (PBSC) in Elderly Patients with Acute Myeloid Leukemia: Results of a Randomized Oligocenter Trial.

Gesine Bug, MD, Steffen Koschmieder, MD, S. Wiebe, MD, Gerd Heil, PhD, Carla Delfs, MD, Wolf-Karsten Hofmann, PhD, Caroline Zander, Juergen Krauter, PhD, Wolfgang Heit, PhD, Arnold Ganser, PhD, Dieter Hoelzer, PhD, Oliver G. Ottmann, PhD
Journal: Blood
Blood (2004) 104 (11): 867.
https://doi.org/10.1182/blood.V104.11.867.867
Published: 2004